Clinical characteristics and prognostic factors of prostate cancer with liver metastases

• Published in: Tumor biology 2014, Vol.35 (1), p.595-601
• Main Authors: Wang, HaiTao, Li, BaoGuo, Zhang, PengYu, Yao, YanHong, Chang, JiWu
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cell adhesion & migration; Humans; Liver cancer; Liver Neoplasms - diagnosis; Liver Neoplasms - mortality; Liver Neoplasms - secondary; Liver Neoplasms - therapy; Male; Metastasis; Middle Aged; Prognosis; Prostate cancer; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Research Article; Survival analysis; Treatment Outcome
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1007/s13277-013-1083-6

Liver metastasis from prostate cancer is uncommon and remains poorly understood. We computer searched the clinical records of all our patients registered into a database to identify patients that presented or developed liver metastases. A total of 27 prostate cancer patients with ultrasound or CT/MR imaging evidence of liver metastases were included in our analysis. The liver metastasis rate from metastatic prostate cancer was 4.29 %. Eight (29.63 %) patients had previously untreated, hormone-naive prostate cancer (synchronous liver metastases at diagnosis of prostate cancer), whereas 19 (70.37 %) patients had already been diagnosed as having hormone-refractory prostate cancer. In the hormone-naive group, the median overall survival after liver metastases diagnosis was 38 months and half of the patients were still alive at the latest follow-up, whereas only 6 months in the hormone-refractory group ( p  = 0.003). High concentration of serum neuron-specific enolase and previous chemotherapy were associated with a significantly poor overall survival after liver metastases in the hormone-refractory group using Kaplan–Meier curves and logrank tests for univariate analysis.